Your browser doesn't support javascript.
loading
Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations.
Ben-Ami, Tal; Kontny, Udo; Surun, Aurore; Brecht, Ines B; Almaraz, Ricardo López; Dragomir, Monica; Pourtsidis, Apostolos; Casanova, Michela; Fresneau, Brice; Bisogno, Gianni; Schneider, Dominik T; Reguerre, Yves; Bien, Ewa; Stachowicz-Stencel, Teresa; Österlundh, Gustaf; Wygoda, Marc; Janssens, Geert O; Zsiros, József; Jehanno, Nina; Brisse, Herve J; Gandola, Lorenza; Christiansen, Hans; Claude, Line; Ferrari, Andrea; Rodriguez-Galindo, Carlos; Orbach, Daniel.
Afiliação
  • Ben-Ami T; Pediatric Hematology-Oncology Unit, Kaplan Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Rehovot, Israel.
  • Kontny U; Division of Pediatric Hematology Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
  • Surun A; SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris, France.
  • Brecht IB; Pediatric Hematology and Oncology, University Children's Hospital, Eberhard-Karls-Universitaet, Tuebingen, Germany.
  • Almaraz RL; Pediatric Hematology and Oncology Unit, Hospital Universitario de Cruces, Barakaldo-Bizkaia, Spain.
  • Dragomir M; Department of Pediatric Oncology, Oncology Institute "Prof. Dr. Al. Trestioreanu,", Bucharest, Romania.
  • Pourtsidis A; Pediatric and Adolescents Oncology Clinic Children's Hospital MITERA, Athens, Greece.
  • Casanova M; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Fresneau B; Gustave Roussy, Department of Pediatric Oncology, Université Paris-Saclay, Villejuif, France.
  • Bisogno G; Paris-Saclay University, Paris-Sud University, Paris, France.
  • Schneider DT; Hematology Oncology Division, Department of Woman's and Child's Health, University of Padova, Padova, Italy.
  • Reguerre Y; Clinic of Pediatrics, Dortmund Municipal Hospital, Dortmund, Germany.
  • Bien E; Department of Pediatric Hematology and Oncology, Félix Guyon University Hospital, St. Denis, Réunion Island, France.
  • Stachowicz-Stencel T; Department of Pediatrics, Hematology and Oncology, Medical University of Gdansk, Gdansk, Poland.
  • Österlundh G; Department of Pediatrics, Hematology and Oncology, Medical University of Gdansk, Gdansk, Poland.
  • Wygoda M; Department of Pediatric Hematology and Oncology, The Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Janssens GO; Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Zsiros J; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Jehanno N; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Brisse HJ; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Gandola L; Department of Nuclear Medicine, Institut Curie, Paris, France.
  • Christiansen H; Department of Radiology, Institut Curie, Paris University, Paris, France.
  • Claude L; Pediatric Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Ferrari A; Department of Radiation Oncology, Hannover Medical School, Hanover, Germany.
  • Rodriguez-Galindo C; Department of Radiation Oncology, Léon Bérard Center, Lyon, France.
  • Orbach D; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Pediatr Blood Cancer ; 68 Suppl 4: e29018, 2021 06.
Article em En | MEDLINE | ID: mdl-33844410
Nasopharyngeal carcinoma (NPC) is a rare pediatric tumor. Collaborative studies performed over the last decades showed improved results compared to historical data, but standardized guidelines for diagnosis and management of pediatric NPC are still unavailable. This study presents a European consensus guideline for the diagnosis and treatment of pediatric NPC developed by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). Main recommendations include induction chemotherapy with cisplatin and 5-flurouracil, concomitant chemoradiotherapy in advanced disease, and to consider maintenance treatment with interferon beta (IFN-ß) for selected high-risk patients. Dose adjustments of radiotherapy based on response to induction chemotherapy may decrease the rates of long-term treatment-related complications that affect most of the survivors.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Neoplasias Nasofaríngeas Tipo de estudo: Diagnostic_studies / Guideline Limite: Adolescent / Child / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Neoplasias Nasofaríngeas Tipo de estudo: Diagnostic_studies / Guideline Limite: Adolescent / Child / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article